• Fluvoxamine maleate

Fluvoxamine maleate

  • CasNo：61718-82-9
  • Purity：99%

Product Details;

CasNo： 61718-82-9

Molecular Formula： C15H21F3N2O2.C4H4O4

Appearance： white crystalline powder

Buy Best Quality 61718-82-9 Fluvoxamine maleate with Competitive Price

  • Molecular Formula:C15H21F3N2O2.C4H4O4
  • Molecular Weight:434.413
  • Appearance/Colour:white crystalline powder 
  • Melting Point:120-121.5 °C 
  • Boiling Point:370.6 °C at 760 mmHg 
  • Flash Point:177.9 °C 
  • PSA：131.44000 
  • LogP:3.61360 

Fluvoxamine maleate(Cas 61718-82-9) Usage

Description

Fluvoxamine maleate is an SSRI with a specific focus on treating obsessive-compulsive disorder (OCD) and panic disorder. It acts by increasing serotonin levels in the brain, leading to improved mood and alleviation of symptoms associated with these mental health conditions. It is important for individuals to use this medication under the guidance of a healthcare provider and be aware of potential side effects.

Chemical Properties

Crystalline Solid

Originator

Duphar (Netherlands)

Uses

Fluvoxamine maleate is a medication belonging to the class of selective serotonin reuptake inhibitors (SSRIs).
Medical Uses

Depression and Obsessive-Compulsive Disorders:

Luvox (fluvoxamine) and Prozac (fluoxetine) are SSRIs used to treat depression and obsessive-compulsive disorders.
Fluvoxamine is specifically used to treat obsessive-compulsive disorder (OCD).
Social Anxiety Disorder:

Luvox is also utilized for the treatment of social anxiety disorder (social phobia).
Extended-Release Capsules:

Fluvoxamine maleate extended-release capsules are prescribed to treat obsessive-compulsive disorder (OCD).

Brand name

Luvox (Solvay Pharmaceuticals);FLOXYFRAL.
Pharmacological Effects In vitro and in vivo animal experiments have shown that fluvoxamine has a marked effect on serotonin (5-HT) mediated processes.

Hazard

A poison by ingestion. Human systemic effects.

Biological Activity

Selective serotonin reuptake inhibitor; antidepressant. Binds to the human 5-HT transporter with a K i of 1.6 nmol/l. Also available as part of the Serotonin Uptake Inhibitor Tocriset? .

Clinical Use

SSRI antidepressant:DepressionObsessive compulsive disorder
Clinical Effects Increased serotonin levels contribute to an improved mood.
Reduced symptoms of OCD and panic disorder are observed with the use of fluvoxamine.
Selective Neuronal Serotonin Reuptake Inhibitor Fluvoxamine is characterized as a selective neuronal serotonin reuptake inhibitor (SNSRI).

InChI:InChI=1/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-

61718-82-9 Relevant articles

Fluvoxamine Maleate in the Treatment of Depression A Single-Center, Double-Blind, Placebo-Controlled Comparison With Imipramine in Outpatients

Claghorn, James L. MD; Earl, Craig Q. PhD; Walczak, Donna D. PhD; Stoner, Kim A. BS; Wong, Lung Fai MS; Kanter, Donald PhD; Houser, Vincent P. PhD

, Journal of Clinical Psychopharmacology 16(2):p 113-120, April 1996.

The majority of these adverse events were mild to moderate and, with the exception of dry mouth (imipramine) and abnormal ejaculation (fluvoxamine), were transient. The data clearly demonstrate the antidepressant activity and tolerability of fluvoxamine maleate (50-150 mg/day) as compared with placebo; it is also as effective as the tricyclic antidepressant imipramine (80-240 mg/day) in patients with major depressive disorder.

Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects

M. H. De Vries, J. Van Harten, P. Van Bemmel, M. Raghoebar

, Biopharmaceutics & Drug Disposition, Volume14, Issue4 May 1993 Pages 291-296

The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100 mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects.

Quantitative Analysis of Fluvoxamine Maleate in Tablet Formulations by HPLC

N. H. Foda

, Journal of Liquid Chromatography Volume 18, 1995 - Issue 8

The recovery and coefficient of variation from six placebo tablets containing 100 mg of fluvoxamine maleate were 100.56% and 0.439% respectively. Relicate regression analyses of three standard plots in the concentration range of 0.5–12 mcg/ml obtained on three different days gave a correlation coefficient > 0.9997 and the coefficient of variation of the slopes < 0.1%.

61718-82-9 Process route

5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one
61718-80-7

5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one

2-chloroethanamine hydrochloride
870-24-6

2-chloroethanamine hydrochloride

maleic acid
110-16-7,26099-09-2

maleic acid

fluvoxamine maleate
61718-82-9,917096-37-8

fluvoxamine maleate

Conditions
Conditions Yield
5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one; 2-chloroethanamine hydrochloride; With potassium hydroxide; In water; dimethyl sulfoxide; toluene; at 40 - 45 ℃;
maleic acid; In water; at 20 - 30 ℃;
161 mg
1-N-hydroxy-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-imine
61747-22-6

1-N-hydroxy-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-imine

2-chloroethanamine hydrochloride
870-24-6

2-chloroethanamine hydrochloride

maleic acid
110-16-7,26099-09-2

maleic acid

fluvoxamine maleate
61718-82-9,917096-37-8

fluvoxamine maleate

Conditions
Conditions Yield
With potassium hydroxide; In water; toluene;
 

61718-82-9 Upstream products

  • 61747-22-6
    61747-22-6

    1-N-hydroxy-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-imine

  • 870-24-6
    870-24-6

    2-chloroethanamine hydrochloride

  • 110-16-7
    110-16-7

    maleic acid

  • 61718-80-7
    61718-80-7

    5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one

61718-82-9 Downstream products

  • 192876-02-1
    192876-02-1

    Demethyl Fluvoxamine

Inquiry

Name:
*CompanyName:
*Email:
*Requirements:
*Code:
Submit